Chitchat PM Lee spare no effort to get young children vaccinated, parental decision-making is critical.

[Hypocrite-The]

mRNA vaccines are better..


'No evidence' inactivated virus vaccines more efficacious against COVID-19 variants than mRNA ones: Singapore expert committee
COVID-19 vaccination at Tanjong Pagar, Singapore (4)
A person receiving a dose of the COVID-19 vaccine at Tanjong Pagar Community Centre on Jan 27, 2021. (Photo: Jeremy Long)
Bookmark
SINGAPORE: There is "no evidence" that inactivated virus vaccines demonstrate higher efficacy against COVID-19 variants than messenger RNA (mRNA)-based vaccines, said the government-appointed expert committee on COVID-19 vaccination in Singapore.

"We have noted social media messages asserting that the mRNA COVID-19 vaccines are ineffective against (variants of concern) and that inactivated virus COVID-19 vaccines would provide superior protection," said the committee in a media release on Monday (Jun 7).

The two vaccines currently used in Singapore's national vaccination programme - Pfizer-BioNTech and Moderna - are based on mRNA technology. Both were recommended by the expert committee and authorised by the Health Science Authority (HSA) under the Pandemic Special Access Route (PSAR).

The committee said its assessment, based on a continual review of data and evidence, remains that the authorised mRNA vaccines are "safe and highly effective" and continue to show protection against the virus variants.

"The inactivated virus COVID-19 vaccines have variable protection and there is currently no evidence to suggest that inactivated virus vaccines demonstrate higher vaccine efficacy against (variants of concerns) than the mRNA vaccines," said the committee.

The Sinovac vaccine, of which Singapore has 200,000 doses, uses inactivated viruses.

Monday's clarification by the expert committee follows a similar statement less than three weeks ago, in response to an open letter by 12 doctors that had called for children to be given COVID-19 vaccines other than mRNA ones over fears of "unknown and unstudied" long-term side effects.

Eleven of the 12 doctors later retracted their statements.

AUTHORISED VACCINES "SAFE AND EFFECTIVE" AGAINST COVID-19

Both the Pfizer-BioNTech and Moderna vaccines have shown to be highly efficacious, especially in protecting against severe COVID-19 disease and hospitalisation, said the committee.

It said the high efficacy of the vaccines was demonstrated in Phase 3 clinical trials, and further supported with data from real-world rollouts of the vaccines, including in the United States, the UK and Israel.

This also includes protection against key COVID-19 variants such as the Alpha and Beta variants, which were the predominant strains circulating in these countries. The Alpha variant, B117, was first detected in the UK while the Beta variant, B1351, was first detected in South Africa.

Infographic Greek names for COVID-19 variants B1617
The committee added that despite concerns over the Delta variant, which was first detected in India, data showed that the mRNA vaccines continue to be effective.

It cited a study in the UK, which showed that two doses of the Pfizer-BioNTech COVID-19 vaccine gave about 88 per cent protection against symptomatic COVID-19, even with the Delta variant.

"While further studies are required before a definitive conclusion can be made, the available data globally indicates that substantial protection is preserved," said the committee.

Commentary: Misinformation threatens Singapore’s COVID-19 vaccination programme
It added that protection given by any vaccine is not 100 per cent and "vaccine-breakthrough" infections can occur, with the emergency and spread of new variants due to mutations.

"The detection of asymptomatic to mild infections locally with the Delta variant does not indicate a lack of protection," it said, adding that the findings are in keeping with global evidence that mRNA vaccines have a "high level" of protection against symptomatic and severe COVID-19 disease.

The committee said both mRNA vaccines were approved by multiple international regulatory bodies. Their manufacturers have also "publicly released" detailed study protocols, as well as openly published their findings to be scrutinised by the scientific community after peer review.

Detailed assessments of the vaccines by regulatory bodies such as the US Food and Drug Administration and the UK Medicines & Healthcare Products Regulatory Agency have also been publicly published.

"In sum, the PSAR-authorised mRNA vaccines have reliable scientific evidence that they are safe and effective, and the (committee) continues to strongly recommend that medically eligible persons should be vaccinated with them," it said.

READ: Pfizer-BioNTech, Moderna and Sinovac: A look at three key COVID-19 vaccines
SINOVAC PROTECTION AGAINST NEW VARIANTS STILL UNKNOWN

The committee said the Sinovac COVID-19 vaccine has yet to meet the requirements for a PSAR authorisation by the HSA. Additional safety and quality data required to meet the standards of the evaluation are still pending.

The Sinovac vaccine, which is developed by China's Sinovac Biotech, has shown variable protection across multiple studies carried out internationally, said the committee.

The most complete analysis of the vaccine showed an efficacy of 51 per cent on per-protocol analysis. However, its protection against newer variants such as the Delta variant and under real-world conditions remain unknown, the committee added.

READ: Sinovac COVID-19 vaccine to be allowed in Singapore under special access route after WHO approval
The Sinovac COVID-19 vaccine was approved for emergency use by the World Health Organization last Tuesday. The WHO recommended that it be used for people aged 18 years and older.

As such, the Sinovac vaccine is currently not an option for children and adolescents globally nor in Singapore under the special access route.

"It is critical that medical professionals do not spread unsubstantiated and unscientific information.

"The public has a right to expect medical professionals to give advice based on fact and not on unproven assertions," said the committee.

It also reminded members of the public to rely on reputable sources of scientific and medical information, as well as verify opinions shared by others against such sources.

 

[Hypocrite-The]

If sinovac is 50% efficacy....that means tiongland will never have herd immunity as 50% can still get the virus..

Covid: What do we know about China's coronavirus vaccines?​

Published14 January

image caption Sinovac is a Beijing-based pharmaceutical company
As the global race to produce a Covid-19 vaccine continues, China appears to have made huge strides, with vaccines from two front-runners - Sinovac and Sinopharm - already making their way abroad.
But what do we know about China's vaccines and how do they compare to those being developed elsewhere?

How does the Sinovac vaccine work?​

The Beijing-based biopharmaceutical company Sinovac is behind the CoronaVac, an inactivated vaccine.
It works by using killed viral particles to expose the body's immune system to the virus without risking a serious disease response.
By comparison the Moderna and Pfizer vaccines being developed in the West are mRNA vaccines. This means part of the coronavirus' genetic code is injected into the body, triggering the body to begin making viral proteins, but not the whole virus, which is enough to train the immune system to attack.
"CoronaVac is a more traditional method [of vaccine] that is successfully used in many well known vaccines like rabies," Associate Prof Luo Dahai of the Nanyang Technological University told the BBC.
"mRNA vaccines are a new type of vaccine and there is [currently] no successful example [of them] being used in the population," Prof Luo adds.
media captionHow will the new Pfizer vaccine work?
On paper, one of Sinovac's main advantages is that it can be stored in a standard refrigerator at 2-8 degrees Celsius, like the Oxford vaccine, which is made from a genetically engineered virus that causes the common cold in chimpanzees.
Moderna's vaccine needs to be stored at -20C and Pfizer's vaccine at -70C.
It means that both Sinovac and the Oxford-AstraZeneca vaccine are a lot more useful to developing countries which might not be able to store large amounts of vaccine at such low temperatures.

How effective is it?​

It's hard to say at this point in time.
One Chinese study published in scientific journal The Lancet, only has information from the first and second phase trials of CoronaVac in China.
Zhu Fengcai, one of the paper's authors, said those results - based on 144 participants in the phase one trial and 600 in the phase two trial - meant the vaccine was "suitable for emergency use".
CoronaVac has been undergoing phase three trials in various countries. Interim data from late-stage trials in Turkey and Indonesia showed that the vaccine was 91.25% and 65.3% effective respectively.
Researchers in Brazil initially said it was 78% effective in their clinical trials, but in January 2021 revised that figure to 50.4% after including more data in their calculations. Earlier in November, their trials were briefly halted after the reported death of a volunteer, but resumed after the death was found to have no links to the vaccine.
Sinovac has been approved for emergency use in high-risk groups in China since July.
In September, Mr Yin of Sinovac said tests were performed on more than 1,000 volunteers, of which "some only showed minor fatigue or discomfort… no more than 5%".

image caption Sao Paolo officials were photographed with the CoronaVac vaccine earlier this month
Prof Luo had said ahead of the phase three results that it was difficult to make comments about the vaccine's efficacy at that point in time "given the limited information available".
"Based on the preliminary data... CoronaVac is likely an effective vaccine, but we do need to wait for the results of the phase three trials," he said.
"These trials are randomised, observer-blind, placebo-controlled... with thousands of participants. This is the only way to prove a vaccine is safe and effective to be used at the population level."

What about the Sinopharm vaccine?​

Sinopharm, a Chinese state-owned company, is developing two Covid-19 vaccines, which, like Sinovac are also inactivated vaccines that work in a similar way.
Sinopharm announced on 30 December that phase three trials of the vaccine showed that it was 79% effective - lower than that of Pfizer and Moderna.
However, the United Arab Emirates, which approved a Sinopharm vaccine earlier this month, said the vaccine was 86% effective, according to interim results of its phase three trial.

image caption Both the UAE and Bahrain have granted emergency use of the vaccine on frontline workers
A company spokeswoman declined to explain the discrepancy, and said detailed results would be released later, said a Reuters report.
But even ahead of the phase three trial results, the vaccine had already been distributed to nearly a million people in China under an emergency programme.
Professor Dale Fisher, of the National University of Singapore, said then that it was "unconventional" to ramp up a vaccine programme without first going through last stage trials.
"It is normal to wait for an analysis of phase three trials before ramping up a vaccine programme through emergency use authorisation," he told news site CNBC.
Earlier in December, Peru suspended trials for the Sinopharm vaccine due to a "serious adverse event" affecting a volunteer. It later said that it lifted the suspension.
A pause in a clinical trial is not unusual. In September, the UK paused trials for another Covid-19 vaccine after a participant had a suspected adverse reaction, resuming after the vaccine was ruled out as the cause.
The spread of the coronavirus within China has for the most part been contained - and life is slowly but surely returning to a "new normal".

Any other vaccine candidates?​

At least two other Covid-19 vaccines are under development in China, according to a recent article in The Conversation.
One of them is CanSino Biologics, which is reportedly in phase three clinical trials in countries including Saudi Arabia.
The other is being developed by Anhui Zhifei Longcom. Its vaccine uses a purified piece of the virus to trigger an immune response, and has recently entered phase three trials, according to the report.

Which countries are signing up for China's vaccines?​

Several Asian countries including Singapore, Malaysia and the Philippines have signed deals with Sinovac, and in January 2021 Indonesia began rolling out its mass vaccination campaign with their vaccine.
Turkey has also approved the Sinovac vaccine for emergency use. The company is also known to have secured other deals with Brazil and Chile.
The United Arab Emirates and Bahrain have approved the Sinopharm vaccine.

How would rollout work for China's vaccines?​

Sinovac will be able to produce 300 million doses a year in its newly built 20,000 sq m production plant, its chairman told state media outlet CGTN.
Like all the other vaccines, it requires two doses, which means it is currently only able to inoculate 150m people a year - just over a tenth of China's population.
Analysts point to China's bid to win the vaccine diplomacy race, which has also reportedly seen China's President Xi Jinping pledge to set aside $2bn for the African continent, while also offering Latin American and Caribbean countries a $1bn loan to buy vaccines. It's unclear what the terms of such a deal might be.
"Beijing... will surely leverage the provision of this life-saving technology for commercial and diplomatic profit," Jacob Mardell, an analyst from MERICS, told ABC news.
"[It] possesses something countries dearly need and will seek to paint the vaccine's provision as an act of charity."

 

[busy123]

Can you provide an assurance it is safe?

yes. it is called common sense you see official statistics? so many jabs no ill effects

 

[NissanViP]

yes. it is called common sense you see official statistics? so many jabs no ill effects

You can keep your "common sense" for yourself, no need to promote something that is no evidence whatsoever to prove otherwise.

 

[laksaboy]

No one is mentioning about the side effects of Sinopharm vaccines?

Everything is written on the manual. Read for yourself, knowledge of Chinese required.

https://www.sammyboy.com/threads/73...onavirus-vaccine-exposed.297856/#post-3300390

 

[capamerica]

You can keep your "common sense" for yourself, no need to promote something that is no evidence whatsoever to prove otherwise.

here you go. Both Moderna and Pfizer will be fully approved within months

and the evidence is over 2 billion shots in over 100 countries with hard results

https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html

Moderna applies for full FDA approval of its Covid vaccine​

PUBLISHED TUE, JUN 1 20218:34 AM EDTUPDATED TUE, JUN 1 20213:57 PM EDT

Berkeley Lovelace Jr.@BERKELEYJR
SHAREShare Article via FacebookShare Article via TwitterShare Article via LinkedIn

Moderna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.
The mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.

“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”
Shares of Moderna were essentially flat in premarket trading.
The FDA approval process is likely to take months.
Moderna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.
WATCH NOW
VIDEO03:11
Moderna to seek FDA emergency approval for its Covid vaccine for ages 12 to 17

Once companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.

CNBC Health & Science​

Read CNBC’s latest global coverage of the Covid pandemic:
EU and U.S. to call for a deeper probe into Covid origins
India reports more than 6,000 daily Covid deaths — highest ever in the world
In China’s new Covid hotspot, police detain those who violate virus prevention measures
Fauci blasts ‘preposterous’ Covid conspiracies, accuses his critics of ‘attacks on science’
Top international health officials worry about new Covid variants that may be able to evade vaccines
Full U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.
Moderna is the second company to seek full U.S. approval of its Covid vaccine. On May 7, Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.
If the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.
Moderna’s vaccine, which requires two doses given four weeks apart, has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.
In addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17. The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.

 

[NissanViP]

here you go. Both Moderna and Pfizer will be fully approved within months

and the evidence is over 2 billion shots in over 100 countries with hard results

https://www.cnbc.com/2021/06/01/covid-vaccine-moderna-applies-for-full-fda-approval.html

Moderna applies for full FDA approval of its Covid vaccine​

PUBLISHED TUE, JUN 1 20218:34 AM EDTUPDATED TUE, JUN 1 20213:57 PM EDT

Berkeley Lovelace Jr.@BERKELEYJR
SHAREShare Article via FacebookShare Article via TwitterShare Article via LinkedIn

Moderna on Tuesday asked the Food and Drug Administration for full U.S. approval of its Covid-19 vaccine — the second drugmaker in the U.S. to seek a biologics license that will allow it to market the shots directly to consumers.
The mRNA vaccine is currently on the U.S. market under an emergency use authorization, which was granted by the FDA in December. It gives conditional approval based on two months of safety data. It’s not the same as a biologics license application, or a request for full approval, which requires at least six months of data. Over 100 million of the shots have already been administered, according to data compiled by the Centers for Disease Control and Prevention.

“We are pleased to announce this important step in the U.S. regulatory process for a Biologics License Application (BLA) of our COVID-19 vaccine,” Moderna CEO Stephane Bancel said in a press release. “We look forward to working with the FDA and will continue to submit data from our Phase 3 study and complete the rolling submission.”
Shares of Moderna were essentially flat in premarket trading.
The FDA approval process is likely to take months.
Moderna will continue to submit data to support the BLA to the FDA on a rolling basis over the coming weeks, the company said Tuesday.
WATCH NOW
VIDEO03:11
Moderna to seek FDA emergency approval for its Covid vaccine for ages 12 to 17

Once companies submit applications to the FDA, agency scientists painstakingly look through the clinical trial data, including for any discrepancies or safety concerns, said Dr. Paul Offit, a voting member of the agency’s Vaccines and Related Biological Products Advisory Committee. “They want to make sure that the company has fairly and accurately displayed all those data,” he said.

CNBC Health & Science​

Read CNBC’s latest global coverage of the Covid pandemic:
EU and U.S. to call for a deeper probe into Covid origins
India reports more than 6,000 daily Covid deaths — highest ever in the world
In China’s new Covid hotspot, police detain those who violate virus prevention measures
Fauci blasts ‘preposterous’ Covid conspiracies, accuses his critics of ‘attacks on science’
Top international health officials worry about new Covid variants that may be able to evade vaccines
Full U.S. approval will allow Moderna’s vaccine to stay on the market once the pandemic is over and the U.S. is no longer in a public health emergency, said former FDA commissioner Dr. Robert Califf. It also sets the stage for the company to begin advertising the shots on TV and other media platforms, he said, which is not permitted under an EUA.
Moderna is the second company to seek full U.S. approval of its Covid vaccine. On May 7, Pfizer and partner BioNTech said they started the process of seeking full approval for their vaccine for use in people 16 and older in the U.S.
If the FDA grants Moderna’s request, it would be the Massachusetts-based company’s first-ever approved product.
Moderna’s vaccine, which requires two doses given four weeks apart, has been found to be more than 90% effective at protecting against Covid and more than 95% effective against severe disease up to six months after the second dose. The company said in an earnings report on May 6 that it planned to begin the process of seeking full FDA approval soon.
In addition to seeking full approval, the company is also expected to ask the FDA to expand the emergency use of its Covid vaccine for adolescents as young as 17. The company said last week its shots were found to be 100% effective in a study of kids ages 12 to 17.

I wonder how do you trust a pharma company with list of past criminal records.

https://www.sammyboy.com/threads/pfizer-company-is-a-habitual-offender.304903/​

 

[Hypocrite-The]

Sinovac chicon vaccines are garbage

Hundreds of Indonesian healthcare workers contract COVID-19 despite vaccination, dozens hospitalised​

A woman receives a shot of the Sinovac COVID-19 vaccine during a mass vaccination for the public at the Patriot Candrabhaga Sadium in Bekasi on the outskirts of Jakarta, Indonesia, Jun 14, 2021. (Photo: AP/Achmad Ibrahim)
17 Jun 2021 03:51PM
(Updated: 17 Jun 2021 04:45PM)

Bookmark​

JAKARTA: More than 350 Indonesian doctors and healthcare workers have contracted COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains.
Most of the doctors were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.
Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90 per cent in the district.
Designated as a priority group, Indonesian healthcare workers were among the first to be vaccinated when the inoculation drive started in January.

READ: 'We are worried,' say Indonesian healthcare workers as COVID-19 takes toll on medical system​

Almost all have received the COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association.
While the number of Indonesian healthcare workers dying from COVID-19 has decreased significantly – dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCOVID-19 – public health experts say the Java hospitalisations are cause for concern.
"The data shows they have the Delta variant so it is no surprise that the breakthrough infection is higher than before because as we know the majority of healthcare workers in Indonesia got Sinovac, and we still don't know yet how effective it is in the real world against the Delta variant," said Dicky Budiman, an epidemiologist from Australia's Griffith University.

READ: Indonesia warns COVID-19 cases may not peak until July as hospitals fill​

A spokesperson from Sinovac and Indonesia's ministry of health were not immediately available for comment on the efficacy of Sinovac's CoronaVac against newer coronavirus variants.
Grappling with one of the worst outbreaks in Asia, with more than 1.9 million cases and 53,000 deaths, there has been a heavy toll on Indonesia's doctors and nurses with 946 deaths.
Many are now experiencing pandemic fatigue and taking an increasingly laissez-faire approach to health protocols after being vaccinated, said Lenny Ekawati, from LaporCOVID-19.
"That phenomenon happens quite often these days, not only within the community but also healthcare workers," she said. "They think because they are vaccinated that they are safe."
But as more cases of the highly transmissible Delta variant are identified in the world's fourth most populous nation, the data is starting to tell a different story.
Across Indonesia, at least five doctors and one nurse have died from COVID-19 despite being vaccinated, according to the data initiative group, although one had only received their first shot.

READ: 'No evidence' inactivated virus vaccines more efficacious against COVID-19 variants than mRNA ones: Singapore expert committee​

In Kudus, one senior doctor has died, said the Indonesian Medical Association, although it is understood he had a comorbidity.
In the Indonesian capital Jakarta, radiologist Dr Prijo Sidipratomo told Reuters he knew of at least half a dozen doctors in the city who had been hospitalised with COVID-19 in the past month despite being vaccinated, with one currently being treated in the intensive care unit.
"It is alarming for us because we cannot rely on vaccinations only," he said, urging people to strictly adhere to health protocols.
Weeks after the Eid Al-Fitr holidays, Indonesia has experienced a surge in cases, with the positivity rate exceeding 23 per cent on Wednesday (Jun 16) and daily cases nearing 10,000, the highest since late February.
In its latest situation report the World Health Organization called for Indonesia to implement a stricter lockdown with increased transmission due to variants of concern and a "drastic increase in bed occupancy rates" necessitating urgent action.

 

[NissanViP]

Sinovac chicon vaccines are garbage

Hundreds of Indonesian healthcare workers contract COVID-19 despite vaccination, dozens hospitalised​

A woman receives a shot of the Sinovac COVID-19 vaccine during a mass vaccination for the public at the Patriot Candrabhaga Sadium in Bekasi on the outskirts of Jakarta, Indonesia, Jun 14, 2021. (Photo: AP/Achmad Ibrahim)
17 Jun 2021 03:51PM
(Updated: 17 Jun 2021 04:45PM)

Bookmark​

JAKARTA: More than 350 Indonesian doctors and healthcare workers have contracted COVID-19 despite being vaccinated with Sinovac and dozens have been hospitalised, officials said, as concerns rise about the efficacy of some vaccines against more virulent virus strains.
Most of the doctors were asymptomatic and self-isolating at home, said Badai Ismoyo, head of the Kudus district health office in Central Java, but dozens were in hospital with high fevers and declining oxygen saturation levels.
Kudus is battling an outbreak believed to be driven by the more transmissible Delta variant which has pushed bed occupancy rates above 90 per cent in the district.
Designated as a priority group, Indonesian healthcare workers were among the first to be vaccinated when the inoculation drive started in January.

READ: 'We are worried,' say Indonesian healthcare workers as COVID-19 takes toll on medical system​

Almost all have received the COVID-19 vaccine developed by Chinese biopharmaceutical company Sinovac, according to the Indonesian Medical Association.
While the number of Indonesian healthcare workers dying from COVID-19 has decreased significantly – dropping from 158 deaths this January to 13 this May, according to data initiative group LaporCOVID-19 – public health experts say the Java hospitalisations are cause for concern.
"The data shows they have the Delta variant so it is no surprise that the breakthrough infection is higher than before because as we know the majority of healthcare workers in Indonesia got Sinovac, and we still don't know yet how effective it is in the real world against the Delta variant," said Dicky Budiman, an epidemiologist from Australia's Griffith University.

READ: Indonesia warns COVID-19 cases may not peak until July as hospitals fill​

A spokesperson from Sinovac and Indonesia's ministry of health were not immediately available for comment on the efficacy of Sinovac's CoronaVac against newer coronavirus variants.
Grappling with one of the worst outbreaks in Asia, with more than 1.9 million cases and 53,000 deaths, there has been a heavy toll on Indonesia's doctors and nurses with 946 deaths.
Many are now experiencing pandemic fatigue and taking an increasingly laissez-faire approach to health protocols after being vaccinated, said Lenny Ekawati, from LaporCOVID-19.
"That phenomenon happens quite often these days, not only within the community but also healthcare workers," she said. "They think because they are vaccinated that they are safe."
But as more cases of the highly transmissible Delta variant are identified in the world's fourth most populous nation, the data is starting to tell a different story.
Across Indonesia, at least five doctors and one nurse have died from COVID-19 despite being vaccinated, according to the data initiative group, although one had only received their first shot.

READ: 'No evidence' inactivated virus vaccines more efficacious against COVID-19 variants than mRNA ones: Singapore expert committee​

In Kudus, one senior doctor has died, said the Indonesian Medical Association, although it is understood he had a comorbidity.
In the Indonesian capital Jakarta, radiologist Dr Prijo Sidipratomo told Reuters he knew of at least half a dozen doctors in the city who had been hospitalised with COVID-19 in the past month despite being vaccinated, with one currently being treated in the intensive care unit.
"It is alarming for us because we cannot rely on vaccinations only," he said, urging people to strictly adhere to health protocols.
Weeks after the Eid Al-Fitr holidays, Indonesia has experienced a surge in cases, with the positivity rate exceeding 23 per cent on Wednesday (Jun 16) and daily cases nearing 10,000, the highest since late February.
In its latest situation report the World Health Organization called for Indonesia to implement a stricter lockdown with increased transmission due to variants of concern and a "drastic increase in bed occupancy rates" necessitating urgent action.

Oh my goodness, unbelievable!
Thanks for sharing!